JP2015048340A - Alcohol metabolism promoting agent - Google Patents
Alcohol metabolism promoting agent Download PDFInfo
- Publication number
- JP2015048340A JP2015048340A JP2013182392A JP2013182392A JP2015048340A JP 2015048340 A JP2015048340 A JP 2015048340A JP 2013182392 A JP2013182392 A JP 2013182392A JP 2013182392 A JP2013182392 A JP 2013182392A JP 2015048340 A JP2015048340 A JP 2015048340A
- Authority
- JP
- Japan
- Prior art keywords
- alcohol
- metabolism
- promoting
- alcohol product
- buttermilk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 230000004060 metabolic process Effects 0.000 title claims abstract description 57
- 230000001737 promoting effect Effects 0.000 title claims abstract description 41
- 235000015155 buttermilk Nutrition 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 20
- 235000016709 nutrition Nutrition 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 abstract description 62
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 8
- 206010019133 Hangover Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010028813 Nausea Diseases 0.000 abstract description 5
- 208000002173 dizziness Diseases 0.000 abstract description 5
- 230000008693 nausea Effects 0.000 abstract description 5
- 150000001298 alcohols Chemical class 0.000 abstract description 4
- 235000013336 milk Nutrition 0.000 abstract description 4
- 239000008267 milk Substances 0.000 abstract description 4
- 210000004080 milk Anatomy 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 14
- 230000037396 body weight Effects 0.000 description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 244000008991 Curcuma longa Species 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- -1 magnesium aluminate Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical group 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、生体内に吸収されたアルコールの代謝生成物である酢酸やアセトンをすみやかに代謝する作用を有し、アルコール摂取の弊害である吐き気などの不快感やめまい、二日酔い等の症状緩和に有用で、安定性及び安全性に優れたアルコール生成物代謝促進剤に関する。本発明は、さらに該アルコール生成物代謝促進剤を含有する、アルコール生成物代謝促進用飲食品、アルコール生成物代謝促進用栄養組成物、又はアルコール生成物代謝促進用医薬品に関する。 The present invention has the effect of promptly metabolizing acetic acid or acetone, which is a metabolite of alcohol absorbed in the living body, to alleviate symptoms such as nausea and other discomfort and dizziness, hangovers, etc., which are harmful to alcohol intake. The present invention relates to an alcohol product metabolism promoter that is useful and excellent in stability and safety. The present invention further relates to a food / beverage product for promoting alcohol product metabolism, a nutritional composition for promoting alcohol product metabolism, or a pharmaceutical product for promoting alcohol product metabolism, comprising the alcohol product metabolism promoting agent.
昔から、適量の飲酒は、健康保持増進のために有効であるとされている。最近の疫学研究によれば、適量の飲酒は、全く酒を飲まない、あるいは多量の飲酒に比べ、死亡率を低下させることが報告されている。また、このような現象は、人種や性別、地域条件などに無関係な、適量の飲酒がもたらす、ストレスの発散ならびに、心筋梗塞や狭心症などの虚血性心疾患の予防による効果であると推察されている。
一方、過剰にアルコールを摂取した場合、血液中のアルコール濃度が上昇し、その濃度が０．４％程度になると、延髄にある呼吸中枢の機能が著しく低下して呼吸困難となり、最悪の場合、死に至る可能性がある。また、過剰にアルコールを摂取した後、８から１４時間程度経過すると、しばしば、頭痛や悪心、嘔吐、過呼吸、心悸亢進、発汗などをともなう二日酔いの症状を呈する。したがって、生体内にアルコール、特に、過剰なアルコールやその代謝生成物が存在する場合には、生体機能に大きな変化をもたらすだけでなく、生命の危険を伴う場合があることから、摂取したアルコールをすみやかに代謝して、生体に無害な状態にすることが重要である。
また、アルコール代謝の過程では、その代謝生成物として、アセトアルデヒドや酢酸、アセトンが生成する。特に、酢酸やアセトンは、二日酔いの原因物質と考えられていることから、ＴＣＡ回路を活性化して酢酸を二酸化炭素と水に分解したり、アセトンの生成を抑制する、あるいは、生成したアセトンを尿や呼気から生体外に積極的に排出することにより、それらの濃度をすみやかに低下させ、生体にとって無害な状態にすることが求められる（非特許文献１、２）。
このため、安全に摂取することが可能で、すみやかにアルコールやその代謝生成物を生体にとって無害な状態にすることが期待できる安定性に優れた飲食品や栄養組成物、医薬品の開発が望まれている。
これまで、アルコールの代謝を促進する食品成分として、ウコンやカフェイン、カテキン等が知られている（特許文献１、２）。
For a long time, proper drinking has been considered effective for health maintenance. Recent epidemiological studies have reported that adequate drinking can reduce mortality compared to not drinking alcohol or drinking too much. In addition, such a phenomenon is the effect of prevention of ischemic heart disease such as myocardial infarction and angina pectoris caused by myocardial infarction and angina pectoris caused by an appropriate amount of drinking regardless of race, gender, and regional conditions. It is inferred.
On the other hand, when alcohol is consumed excessively, the alcohol concentration in the blood rises, and when that concentration reaches about 0.4%, the function of the respiratory center in the medulla remarkably decreases, making it difficult to breathe. There is a possibility of death. In addition, after about 14 to 14 hours have passed after excessive intake of alcohol, symptoms of hangover often accompanied by headache, nausea, vomiting, hyperventilation, increased heart rate, sweating and the like are exhibited. Therefore, in the presence of alcohol in the living body, especially excessive alcohol and its metabolites, it not only causes major changes in biological functions, but also may be life-threatening. It is important to quickly metabolize and make it harmless.
In the process of alcohol metabolism, acetaldehyde, acetic acid, and acetone are produced as metabolites. In particular, since acetic acid and acetone are considered as causative substances for hangovers, the TCA circuit is activated to decompose acetic acid into carbon dioxide and water, suppress the production of acetone, or the produced acetone is urine. It is required that the concentration of these substances be rapidly reduced to be harmless to the living body by positively discharging the breath and exhalation outside the living body (Non-patent Documents 1 and 2).
Therefore, it is desirable to develop foods, beverages, nutritional compositions, and pharmaceuticals with excellent stability that can be safely ingested and can be expected to promptly render alcohol and its metabolites harmless to the living body. ing.
So far, turmeric, caffeine, catechin, and the like are known as food ingredients that promote alcohol metabolism (Patent Documents 1 and 2).
特許文献１、２に開示のウコン、カフェイン又はカテキン等を多量に摂取した場合、肝臓に悪影響を及ぼす可能性がある。また、カフェインには不眠やめまい、不安といった副作用があり、多量にカフェインを摂取した場合には中毒症状を呈することが知られている。 When a large amount of turmeric, caffeine, catechin or the like disclosed in Patent Documents 1 and 2 is ingested, there is a possibility of adversely affecting the liver. In addition, caffeine has side effects such as insomnia, dizziness, and anxiety, and it is known that when a large amount of caffeine is ingested, it exhibits addiction symptoms.
本発明は、生体内に吸収されたアルコールの代謝生成物である酢酸やアセトンをすみやかに代謝する作用を有し、アルコール摂取の弊害である吐き気などの不快感やめまい、二日酔い等の症状軽減に有用な、日常的に安全に摂取することが出来るアルコール生成物代謝促進剤、及び該アルコール生成物代謝促進剤を配合したアルコール生成物代謝促進用飲食品、アルコール生成物代謝促進用栄養組成物、又はアルコール生成物代謝促進用医薬品を提供することを課題とする。 The present invention has the effect of promptly metabolizing acetic acid or acetone, which is a metabolite of alcohol absorbed in the living body, to reduce discomfort and dizziness such as nausea that are harmful to alcohol intake, and symptoms such as hangover. Useful alcohol product metabolism promoter that can be safely consumed on a daily basis, food and drink for promoting alcohol product metabolism, and nutrition composition for promoting alcohol product metabolism, comprising the alcohol product metabolism promoter, Another object is to provide a drug for promoting alcohol product metabolism.
本発明者らは、上記の課題を解決するため鋭意検討を進めたところ、バターミルクに、顕著なアルコール生成物代謝促進効果あることを見出した。
すなわち本発明は、以下の様態を含むものである。
（１）バターミルクを有効成分とするアルコール生成物代謝促進剤。
（２）（１）に記載のアルコール生成物代謝促進剤を含むことを特徴とするアルコール生成物代謝促進用飲食品、アルコール生成物代謝促進用栄養組成物、又はアルコール生成物代謝促進用医薬品。
（３）（１）乃至（２）のいずれかに記載のアルコール生成物代謝促進剤を経口摂取することによるアルコール代謝を促進する方法。
As a result of diligent studies to solve the above-mentioned problems, the present inventors have found that buttermilk has a remarkable alcohol product metabolism promoting effect.
That is, the present invention includes the following modes.
(1) An alcohol product metabolism promoter comprising buttermilk as an active ingredient.
(2) A food / beverage product for promoting alcohol product metabolism, a nutritional composition for promoting alcohol product metabolism, or a pharmaceutical product for promoting alcohol product metabolism, comprising the alcohol product metabolism promoting agent according to (1).
(3) A method for promoting alcohol metabolism by orally ingesting the alcohol product metabolism promoter according to any one of (1) to (2).
本発明のアルコール生成物代謝促進剤は、生体内に吸収されたアルコールの代謝生成物である酢酸やアセトンを代謝する作用が顕著であり、アルコール摂取の弊害である吐き気などの不快感やめまい、二日酔い等の症状軽減に有用である。 The alcohol product metabolism promoter of the present invention has a remarkable effect of metabolizing acetic acid and acetone, which are metabolites of alcohol absorbed in the living body, and unpleasantness and dizziness such as nausea that are harmful to alcohol intake, Useful for reducing symptoms such as hangovers.
本発明のアルコール生成物代謝促進剤の有効成分であるバターミルクは、公知の方法でヒト、ウシ、水牛、ヤギ、ヒツジ等の哺乳類の乳から調製されたものや市販されているバターミルクを使用することが可能である。例えば、バターミルクは、生乳から分離した脂肪分４０重量％以上のクリームや発酵クリーム、ホエイクリーム等を原料としてチャーン等を用いてチャーニング（剪断処理）することによって脂肪球を破壊・融合してバターを製造する際に排出される脂肪分１から１５重量％の水相成分として得ることができる。また、上記のように調製したバターミルクは、通常、食品や医薬品を製造する際に使用される熱等による殺菌処理をすること、ならびに凍結乾燥や噴霧乾燥等により乾燥することが可能である。 As the buttermilk which is an active ingredient of the alcohol product metabolism promoter of the present invention, a buttermilk prepared from milk of mammals such as humans, cows, buffaloes, goats and sheep by a known method or commercially available buttermilk is used. Is possible. For example, buttermilk breaks and fuses fat globules by churning (shearing) with churn and the like using cream, fermented cream, whey cream, etc. with a fat content of 40% by weight or more separated from raw milk. It can be obtained as an aqueous phase component having a fat content of 1 to 15% by weight discharged when producing butter. In addition, the buttermilk prepared as described above can be sterilized by heat or the like usually used for producing foods and pharmaceuticals, and can be dried by freeze drying, spray drying, or the like.
本発明のバターミルクは、そのままアルコール生成物代謝促進剤として使用してもよいが、必要に応じて、常法に従い、粉末剤、顆粒剤、錠剤、カプセル剤、ドリンク剤等に製剤化して用いることも出来る。また、凍結乾燥や噴霧乾燥等により乾燥したバターミルクも、そのままアルコール生成物代謝促進剤として使用することが可能であり、常法に従い、製剤化して用いることもできる。
さらに、これらを製剤化した後に、これを栄養剤やヨーグルト、飲料、ウエハース等の飲食品、栄養組成物及び医薬品に配合することも可能である。
The buttermilk of the present invention may be used as an alcohol product metabolism promoter as it is, but if necessary, formulated into powders, granules, tablets, capsules, drinks, etc. according to conventional methods. You can also Also, buttermilk dried by freeze-drying, spray-drying or the like can be used as it is as an alcohol product metabolism promoter, and can be formulated and used according to a conventional method.
Furthermore, after formulating them, they can be blended with foods and drinks such as nutrients, yogurt, beverages, wafers, nutritional compositions and pharmaceuticals.
本発明のアルコール生成物代謝促進用飲食品、アルコール生成物代謝促進用栄養組成物及びアルコール生成物代謝促進用医薬品とは、このバターミルクのみを含む場合の他に、安定剤や糖類、脂質、フレーバー、ビタミン、ミネラル、フラボノイド、ポリフェノール等、他の飲食品や医薬に通常含まれる原材料等を含有することができる。また、本発明の有効成分であるバターミルクに加えて、アルコール代謝促進作用を示す他の成分、例えば、ウコンやカフェイン、カテキン等とともに使用することも可能である。 The alcohol product metabolism promoting food and drink, the alcohol product metabolism promoting nutrition composition and the alcohol product metabolism promoting medicinal product of the present invention include not only the buttermilk alone, but also stabilizers, saccharides, lipids, Flavors, vitamins, minerals, flavonoids, polyphenols, and other raw materials usually contained in other foods and beverages and medicines can be contained. Moreover, in addition to the butter milk which is an active ingredient of the present invention, it can be used together with other ingredients exhibiting an alcohol metabolism promoting action, such as turmeric, caffeine, catechin and the like.
アルコール生成物代謝促進用飲食品、アルコール生成物代謝促進用栄養組成物及びアルコール生成物代謝促進用医薬品におけるバターミルクの配合量については、バターミルクが乳等に由来する食品であることから、特に制限はなく、安全性に全く問題はない。但し、本発明でアルコール生成物代謝促進効果を発揮させるためには、成人一人一日あたり本発明のバターミルクを１００ｍｇ以上経口摂取できるように、飲食品や栄養組成物、医薬等へ配合することが好ましい。 Regarding the amount of butter milk in foods and drinks for promoting alcohol product metabolism, nutritional compositions for promoting alcohol product metabolism, and pharmaceuticals for promoting alcohol product metabolism, especially since butter milk is a food derived from milk, etc. There is no limit and there is no safety problem. However, in order to exert the alcohol product metabolism promoting effect in the present invention, it should be blended into foods and drinks, nutritional compositions, medicines, etc. so that 100 mg or more of the buttermilk of the present invention can be orally taken per adult day. Is preferred.
本発明のアルコール生成物代謝促進剤は、上記の有効成分に適当な助剤を添加して任意の形態に製剤化して、経口投与が可能なアルコール生成物代謝促進用組成物とすることができる。製剤化に際して、通常使用される充填剤、増量剤、結合剤、崩壊剤、界面活性剤、滑沢剤等の希釈剤又は賦形剤を用いることができる。賦形剤としては、例えばショ糖、乳糖、デンプン、結晶性セルロース、マンニット、軽質無水珪酸、アルミン酸マグネシウム、合成珪酸アルミニウム、メタ珪酸アルミン酸マグネシウム、炭酸カルシウム、炭酸水素ナトリウム、リン酸水素カルシウム、カルボキシルメチルセルロースカルシウム等の１種又は２種以上を組み合わせて加えることができる。 The alcohol product metabolism promoter of the present invention can be formulated into an arbitrary form by adding an appropriate auxiliary agent to the above active ingredient to obtain an alcohol product metabolism promoting composition that can be administered orally. . In the formulation, diluents or excipients such as fillers, extenders, binders, disintegrants, surfactants, lubricants and the like that are usually used can be used. Examples of excipients include sucrose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicic acid, magnesium aluminate, synthetic aluminum silicate, magnesium magnesium metasilicate, calcium carbonate, sodium bicarbonate, calcium hydrogen phosphate. One or two or more of carboxymethylcellulose calcium and the like can be added in combination.
以下に実施例、試験例を示し、本発明について詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples. However, these are merely illustrative, and the present invention is not limited thereto.
（バターミルクの製造）
生乳から分離したクリーム（脂肪分４７％）１０ｋｇをメタルチャーンで剪断処理することにより、バターと水相画分であるバターミルクに分離した。このバターミルクを凍結乾燥して、バターミルクの粉末（実施例品１）４４０ｇを得た。このバターミルクの粉末には、全乳固形分中、脂肪が７．３％、タンパク質が３２．５％、炭水化物が５２．５％、灰分が７．７％含まれていた。このようにして得られたバターミルクの粉末は、そのまま本発明のアルコール生成物代謝促進剤として使用可能である。
(Manufacture of buttermilk)
10 kg of cream (fat content 47%) separated from raw milk was sheared with metal churn to separate butter and buttermilk which is an aqueous phase fraction. This buttermilk was freeze-dried to obtain 440 g of buttermilk powder (Example Product 1). This buttermilk powder contained 7.3% fat, 32.5% protein, 52.5% carbohydrate, and 7.7% ash in the total milk solids. The powder of buttermilk thus obtained can be used as it is as the alcohol product metabolism promoter of the present invention.
［試験例１］
バターミルクのアルコール生成物代謝促進効果を調べた。
７週齢の雄性ＩＣＲ系マウスを９匹ずつ、実施例品１のバターミルクをマウス体重１ｋｇあたり１００ｍｇ投与するＢ群、実施例品１のバターミルクからクロロホルム−メタノール（２：１）溶液、アセトン、フロロシルカラム、シリカゲルカラムを用いてスフィンゴミエリンを除き、既報（Ｈａｒｕｔａ， Ｙ． ｅｔ． ａｌ． ： Ｂｉｏｓｃｉｅｎｃｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， ａｎｄ Ｂｉｏｃｈｅｍｉｓｔｒｙ， ７２ ：２１５１−２１５７， ２００８）に従いリン脂質の組成を測定したところ、ホスファチジルエタノールアミンとホスファチジルコリン、ホスファチジルイノシトール、ホスファチジルセリンを４３：４６：７：４で含むものをマウス体重１ｋｇあたり１００ｍｇ投与するＣ群に分けた。それぞれをゾンデで経口投与した１時間後に、マウス体重１ｋｇあたり２ｇになるようにエタノールを投与し、その１時間後に採血して、血液に含まれる酢酸とアセトンの濃度を測定した。また、陽性対象として、カフェインをマウス体重１ｋｇあたり２００ｍｇ投与するＤ群とスフィンゴミエリンをマウス体重１ｋｇあたり１６ｍｇ投与するＥ群を設定し、溶媒である水のみを投与するＡ群（コントロール）と比較した。その結果を表１に示す。
バターミルク及びバターミルクからスフィンゴミエリンを除いたものをマウス体重１ｋｇあたり１００ｍｇ投与したＢ群ならびにＣ群の血液中の酢酸濃度やアセトン濃度は、コントロール（Ａ群）に比べ有意に低下した。一方、カフェインをマウス体重１ｋｇあたり２００ｍｇ投与したＤ群の血液中の酢酸濃度やアセトン濃度は、コントロール（Ａ群）に比べ有意に増加した。また、スフィンゴミエリンをマウス体重１ｋｇあたり１６ｍｇ投与したＥ群の血液中の酢酸濃度やアセトン濃度は、コントロール（Ａ群）と同等であった。したがって、本発明のバターミルクは、体内に吸収されたエタノールの代謝生成物である酢酸やアセトンをすみやかに代謝する作用を有し、その効果は、マスウ体重１ｋｇあたり１００ｍｇ以上摂取した場合に認められることが明らかとなった。
[Test Example 1]
The alcohol product metabolism promoting effect of buttermilk was investigated.
Nine 7-week-old male ICR mice, 100 mg / kg body weight of buttermilk of Example Product 1 were administered in Group B, Buttermilk of Example Product 1 in chloroform-methanol (2: 1) solution, acetone Sphingomyelin was removed using a fluorosil column and a silica gel column, and the composition of the phospholipid was measured according to the previous report (Haruta, Y. et. Al .: Bioscience Biotechnology, and Biochemistry, 72: 2151-2157, 2008). Those containing phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol, and phosphatidylserine at 43: 46: 7: 4 were divided into groups C to be administered at 100 mg / kg of mouse body weight. One hour after each oral administration with a sonde, ethanol was administered so that the mouse body weight was 2 g / kg, and blood was collected after 1 hour, and the concentrations of acetic acid and acetone contained in the blood were measured. In addition, as positive subjects, a group D in which 200 mg of caffeine is administered per kg of mouse body weight and a group E in which sphingomyelin is administered of 16 mg per kg of mouse body weight are set, and compared with group A (control) in which only water as a solvent is administered. did. The results are shown in Table 1.
The concentrations of acetic acid and acetone in the blood of Group B and Group C administered with 100 mg / kg of mouse body weight of buttermilk and buttermilk excluding sphingomyelin significantly decreased compared to the control (Group A). On the other hand, the acetic acid concentration and the acetone concentration in the blood of Group D administered with 200 mg of caffeine per kg of mouse body weight were significantly increased compared to the control (Group A). Moreover, the acetic acid concentration and the acetone concentration in the blood of the E group which administered 16 mg of sphingomyelin per kg body weight of the mouse were equivalent to the control (Group A). Therefore, the buttermilk of the present invention has a function of quickly metabolizing acetic acid and acetone, which are metabolites of ethanol absorbed in the body, and the effect is observed when 100 mg or more of 1 kg of trout body weight is ingested. It became clear.
※は、コントロール（Ａ群）と比較して有意差があることを示す（ｐ＜０．０５）。
* Indicates that there is a significant difference compared to the control (Group A) (p <0.05).
（アルコール生成物代謝促進用カプセル剤の調製）
表２に示す配合で原材料を混合した後、常法により造粒し、カプセルに充填して、本発明のアルコール生成物代謝促進用カプセル剤を製造した。
(Preparation of capsules for promoting alcohol product metabolism)
After mixing the raw materials with the formulation shown in Table 2, the mixture was granulated by a conventional method and filled into capsules to produce a capsule for promoting alcohol product metabolism of the present invention.
（アルコール生成物代謝促進用錠剤の調製）
表３に示す配合で原材料を混合した後、常法により１ｇに成型、打錠して本発明のアルコール生成物代謝促進用錠剤を製造した。
(Preparation of tablets for promoting alcohol product metabolism)
After mixing the raw materials with the formulation shown in Table 3, it was molded and tableted into 1 g by a conventional method to produce the alcohol product metabolism promoting tablet of the present invention.
（アルコール生成物代謝促進用液状栄養組成物の調製）
実施例品１のバターミルク５０ｇを４，９５０ｇの脱イオン水に溶解し、５０℃まで加熱後、ＴＫホモミクサー（ＴＫ ＲＯＢＯ ＭＩＣＳ；特殊機化工業社製）にて、６，０００ｒｐｍで３０分間撹拌混合して５０ｇ／５ｋｇのバターミルク溶液を得た。このバターミルク溶液５．０ｋｇに、カゼイン５．０ｋｇ、大豆タンパク質５．０ｋｇ、魚油１．０ｋｇ、シソ油３．０ｋｇ、デキストリン１７．０ｋｇ、ミネラル混合物６．０ｋｇ、ビタミン混合物１．９５ｋｇ、乳化剤２．０ｋｇ、安定剤４．０ｋｇ、香料０．０５ｋｇを配合し、２００ｍｌのレトルトパウチに充填し、レトルト殺菌機 (第１種圧力容器、ＴＹＰＥ: ＲＣＳ−４ＣＲＴＧＮ、日阪製作所製)で１２１℃、２０分間殺菌して、本発明のアルコール生成物代謝促進用液状栄養組成物５０ｋｇを製造した。
(Preparation of liquid nutritional composition for promoting alcohol product metabolism)
50 g of buttermilk of Example product 1 was dissolved in 4,950 g of deionized water, heated to 50 ° C., and then stirred at 6,000 rpm for 30 minutes with a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). Mixing gave a 50 g / 5 kg buttermilk solution. 5.0 kg of this buttermilk solution, 5.0 kg of casein, 5.0 kg of soy protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 17.0 kg of dextrin, 6.0 kg of mineral mixture, 1.95 kg of vitamin mixture, emulsifier 2 0.0kg, 4.0kg stabilizer, 0.05kg fragrance, filled in 200ml retort pouch, 121 ° C with retort sterilizer (first pressure vessel, TYPE: RCS-4CRTGN, manufactured by Nisaka Seisakusho) By sterilizing for 20 minutes, 50 kg of the liquid nutrition composition for promoting alcohol product metabolism of the present invention was produced.
（アルコール生成物代謝促進用飲料の調製）
脱脂粉乳３００ｇを４００ｇの脱イオン水に溶解した後、実施例品１のバターミルク１０ｇを溶解し、５０℃まで加熱後、ウルトラディスパーサー（ＵＬＴＲＡ−ＴＵＲＲＡＸ Ｔ−２５；ＩＫＡジャパン社製）にて、９，５００ｒｐｍで３０分間撹拌混合した。マルチトール１００ｇ、酸味料２ｇ、還元水飴２０ｇ、香料２ｇ、脱イオン水１６６ｇを添加した後、１００ｍｌのガラス瓶に充填し、９５℃、１５秒間殺菌後、密栓し、本発明のアルコール生成物代謝促進用飲料１０本（１００ｍｌ入り）を調製した。
(Preparation of alcohol product metabolism promoting beverage)
After dissolving 300 g of skim milk powder in 400 g of deionized water, 10 g of buttermilk of Example Product 1 was dissolved, heated to 50 ° C., and then ultradispersed (ULTRA-TURRAX T-25; manufactured by IKA Japan). The mixture was stirred and mixed at 9,500 rpm for 30 minutes. Add 100 g of maltitol, 2 g of acidulant, 20 g of reduced starch syrup, 2 g of fragrance, and 166 g of deionized water, then fill into a 100 ml glass bottle, sterilize at 95 ° C. for 15 seconds, and seal to promote the metabolism of the alcohol product of the present invention 10 beverages (with 100 ml) were prepared.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013182392A JP6309225B2 (en) | 2013-09-03 | 2013-09-03 | Alcohol product metabolism promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013182392A JP6309225B2 (en) | 2013-09-03 | 2013-09-03 | Alcohol product metabolism promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015048340A true JP2015048340A (en) | 2015-03-16 |
| JP6309225B2 JP6309225B2 (en) | 2018-04-11 |
Family
ID=52698638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182392A Active JP6309225B2 (en) | 2013-09-03 | 2013-09-03 | Alcohol product metabolism promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6309225B2 (en) |
-
2013
- 2013-09-03 JP JP2013182392A patent/JP6309225B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| "Ways to Cure your Hangover", DUMB LITTLE MAN [ONLINE], JPN6017013958, November 2006 (2006-11-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6309225B2 (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007246404A (en) | Learning ability-improving agent | |
| WO2013161820A1 (en) | Composition for promoting bifidobacteria growth | |
| JP2008013473A (en) | Muscle hypofunction inhibitor | |
| TW201200037A (en) | Nutritional powders comprising spray dried HMB | |
| RU2668871C2 (en) | New preventive application for prevention of infections | |
| JPWO2016013617A1 (en) | Brain function improving agent and preventive or therapeutic agent for cognitive impairment | |
| RU2762096C2 (en) | Bifidobacteria for reducing food, energy and/or fat consumption | |
| JP6203577B2 (en) | Alcohol product metabolism promoter | |
| JP6072516B2 (en) | Allergy improving agent | |
| JP6309225B2 (en) | Alcohol product metabolism promoter | |
| JP7263426B2 (en) | obesity inhibitor | |
| JP2006335725A (en) | Composition for improving bloodstream | |
| JP2004262927A (en) | Serum cholesterol-reducing agent, food or drink, and method for producing the same | |
| JP7025112B2 (en) | BDNF production promoter | |
| JP2004083526A (en) | Antiviral composition | |
| JP2009149550A (en) | Lipid absorption promoter | |
| WO2017146141A1 (en) | Rehydration agent | |
| WO2016186115A1 (en) | Urinary system symptom amelioration agent | |
| JP7316035B2 (en) | Drowsiness suppressant and food/beverage for suppressing drowsiness | |
| JPWO2018123873A1 (en) | Composition for promoting sweating | |
| CN112514996B (en) | Combination or composition, dairy product and use | |
| JP6537887B2 (en) | Vertigo improving agent | |
| JPWO2016208641A1 (en) | Composition for increasing blood hemoglobin | |
| JP2006290856A (en) | Prophylactic agent for colon-cancer | |
| JP6629859B2 (en) | Fatigue reducer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170421 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20171108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180309 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180314 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6309225 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |